DUG FY26 slides: record revenue, margin gains amid market skepticism
DUG FY26 slides: record revenue, margin gains amid market skepticism
Day: August 27, 2026
Mpm Bioventures sells $461,545 in Entrada Therapeutics stock
Mpm Bioventures sells $461,545 in Entrada Therapeutics stock
Thinking Machines Lab cofounder Barret Zoph joins Google
Zoph will join Google’s DeepMind as Vice President of Research after serving as Vice President of Research at OpenAI.
Mpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock
Mpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock
Earnings call transcript: Credit Clear lifts FY2026 profit as U.K. push grows
Earnings call transcript: Credit Clear lifts FY2026 profit as U.K. push grows
Earnings call transcript: Sunny Optical H1 2026 profit rises, shares gain 5.2%
Earnings call transcript: Sunny Optical H1 2026 profit rises, shares gain 5.2%
Augmont Enterprises IPO allotment today; GMP at 40% hints at strong listing. Here’s how to check status
Following the allotment, shares for successful applicants are expected to be credited to their demat accounts ahead of the company’s market debut. Augmont Enterprises is scheduled to list on both the BSE and NSE on August 31, 2026.
Asian chip stocks mixed after Nvidia results as outlook diverges
Asian chip stocks mixed after Nvidia results as outlook diverges
Annu Projects IPO Day 3: GMP, subscription status and key details. Should you subscribe?
The Rs 175.06 crore Annu Projects IPO entered its third day of bidding on August 27, with the issue subscribed 47% on Day 2. The IPO has attracted stronger retail participation, while its grey market premium (GMP) stands at around Rs 4, indicating a potential listing gain of about 4%. With the issue closing on…
Symbiotec Pharmalab IPO Day 4: GMP at 29%, subscription reaches 5.31x — Should you subscribe?
Symbiotec Pharmalab IPO enters its final bidding day with 5.31 times overall subscription and a Rs 285 GMP. The Rs 1,757 crore issue is priced at Rs 938–988 per share, with listing expected on September 1. Proceeds will partly repay debt, while investors weigh strong demand against premium valuation and risks.